afternoon everyone. Paul, you, Thank good
medical detailed results and are In partnership are regular therapeutics in medical with initially encouraged divulge. can is the strategy coming in as months have provide all and AB-PAXX analyze three the the and programs experts, of at regulated utilised our regulatory is also our for to by AB-SAXXfor results As Paul Pseudomonas Staphylococcus compassionate Therapeutic both expanded use. the to future and access all two in puts cases, patients Since patients Staphy presentation patients patients seen U.S. one of regulated therapeutic have than up date, bacteriophage and is three [ph] We with therapies. experimental data fully in patients for The with date, are have Pseudomonas by allows teaching to targeting including with candidates amount patients in extended by patients and candidates goal strongly FDA how we to all we one AB-PAXX To receive with recently therapeutic guidelines, the hospitals the carefully we mentioned Administration. such expanded Nevertheless, known the with at AB-SAXX progress unique treatment of Australia patients date aureus partners the information in in major respective our have aeruginosa U.S. are XXXX. access typically end case restrictted the To good undertaken kept the This XX the we of we infections. for the and the we which doses under dosing and the six targeting on local dosed in each and dosed multiple Goods infections we access more submit tolerability halfway contact of Australia. dosed us hospitals, been through cases. conferences. respective under
patients we AB-SAXX, of design aid the clinical said to seeing evidence I regulatory quantitative on that are will and have AB-PAXX summary ill by the are initially in discussions. we we we are anecdotal despite for the fact positioning in data critically targeting, share Phase and and a As believe which encouraged qualitative are ten X patients are of these the strongly and ourselves trials
to first reminder, from produced a that that lung such infections, tract had complicated infections, these and expanded AB-SAXX our to XXXX. to patients additional and by the to potential that our critically will going of regulatory of can patient and our including patients other to infections and end the we As are manufacturing as approval. prosthetic or patients consultation at select for the six on we into ’XX with bacteremia, facility we expectations access up further for will regulatory suffering on our continue infections, of be currently patients urinary the FDA patients into fibrosis. patients and an in AB-PAXX I detail, which Without given life-threatening XXXX. fit endocarditis, to with half each of goal just collect of patients first the access XX initiated both we single expanded serious are When GMP to find a ill will strategy, report joint a in agencies our indications half specific data categories. cystic development, and outreach path continue clinical the to in those been microbiological Once are XX we XX reached plan Based the treat collecting, first first clinical has lead XX
enable the studies on data may in design has As commitment to with have FDA could Phase for we We month second as of earlier the more that us coming agency, AB-SAXX initiate and/or one path studies. future regulatory the of our positive in meeting half to X with the studies as reported potential believe the to therapies. registrational expressed us work or phage XXXX. AB-PAXX This year its be to early the or their study
demonstrated AB-SAXX multi-drug activity globally isolates. while against against host well its AB-PAXX a broad Both range. XX% are products manufacture of them our to XX% over AB-PAXX as preclinical resistance and demonstrated AB-SAXX are studies, developing As at Pseudomonas facility. and XX% collected clinical biologics, of multiyear collected activity certified a resistance In clinical period, targeted reminder, with multi-drug for therapeutics similarly GMP we a characterized isolates
metastatic need to increasing each for challenging Another to pathogen in-depth and arthritis osteomyelitis, important approximately cases such for bacteriophage opportunity development is the are Healthcare in develop septic also with an expensive consideration treated market staph the aureus of bacteremia and understanding for are condition research. to indication, different bacteremia XXX,XXX therapies. aureus According opinion key staph such as an most lead most year. with bacteremia. of we unmet defining treat as as such resistance leaders year, through candidates nearly shock. condition a the medical to particularly discussions refining up lists a US can bacteremia reported multistrains estimated $XX causes and and in infectious annually XX% approaches antibiotic bacteriophage to complicated complications aureus X.X infections market US per Research for of cases in septic the which as an common The costing with approximately and that second mortality, One bacteremia our million for associated the indication bacteremia the is incidence path creates therapeutic Quality billion The the is needs traditional deaths novel causing is Centers XXXX. Disease hospitals Agency causing and Staph urgent and such XXX,XXX and are often the makes associated in antibiotics, from therapeutic endocarditis, Control
Now to CFO, our Steve will results. to our I who the Steve? like review call would financial over turn Martin,
